Targeting brain lipid homeostasis to treat Alzheimer's disease

针对脑脂质稳态来治疗阿尔茨海默病

• 批准号: FT0991986
• 负责人: Prof Brett Garner
• 金额: $ 56.26万
• 依托单位: University of Wollongong
• 依托单位国家: 澳大利亚
• 项目类别: ARC Future Fellowships
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/FT0991986
• 关键词: Targeting; brain; lipid; homeostasis; treat

Dementia affects approximately 250,000 people in Australia at an estimated cost (in 2002) of $6.6 billion per annum. The major cause of dementia (accounting for approximately 70% of all cases) is Alzheimer's disease (AD); a progressive neurodegenerative illness for which there is no curative or disease-stalling treatment. Due to increases in life expectancy, the incidence of AD is predicted to triple by 2050 unless disease-modifying treatments are developed. This research program will provide novel realistic pharmaceutical approaches to treat AD. Even if the onset of AD could be delayed by a few years the personal and financial benefits would be enormous. The potential for this research to generate commercially viable Australian intellectual property is also significant.

在澳大利亚，痴呆症影响着大约25万人，估计每年的费用（2002年）为66亿美元。痴呆症的主要原因（约占所有病例的70%）是阿尔茨海默病（AD）；顽固性痴呆一种进行性神经退行性疾病，没有治愈或延缓疾病的治疗方法由于预期寿命的增加，除非开发出改善疾病的治疗方法，否则预计到2050年阿尔茨海默病的发病率将增加两倍。该研究项目将为阿尔茨海默病的治疗提供新颖、现实的药物治疗方法。即使阿尔茨海默病的发病可以推迟几年，个人和经济利益也将是巨大的。这项研究产生商业上可行的澳大利亚知识产权的潜力也很重要。